DexCom, Inc. (DXCM) NASDAQ

64.02

-1.66(-2.53%)

Updated at April 10 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Jacob Steven Leach	Interim Chief Executive Officer, President & Chief Operating Officer	693,108	1978
Kevin Ronald Sayer	Executive Chairman & Chief Executive Officer (Leave of Absence)	1.29M	1958
Girish Naganathan	Executive VP & CTO	423,920	1978
Sadie Stern	Executive VP & Chief Human Resources Officer	550,829	1975
Michael Brown	Executive VP & Chief Legal Officer	607,236	1970
Jereme Sylvain	Executive VP, CFO & Chief Accounting Officer	621,949	1980
Donald Abbey	Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs	766,800	1967
Jon Coleman	Executive VP & Chief Commercial Officer	0	1964
Matthew Dolan	Executive Vice President of Strategy & Corporate Development	0	1981
Sean Christensen	Vice President of Finance and Investor Relations	0	N/A

Name

Title

Pay

Year Born

Jacob Steven Leach

Interim Chief Executive Officer, President & Chief Operating Officer

693,108

1978

Kevin Ronald Sayer

Executive Chairman & Chief Executive Officer (Leave of Absence)

1.29M

1958

Girish Naganathan

Executive VP & CTO

423,920

1978

Sadie Stern

Executive VP & Chief Human Resources Officer

550,829

1975

Michael Brown

Executive VP & Chief Legal Officer

607,236

1970

Jereme Sylvain

Executive VP, CFO & Chief Accounting Officer

621,949

1980

Donald Abbey

Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs

766,800

1967

Jon Coleman

Executive VP & Chief Commercial Officer

1964

Matthew Dolan

Executive Vice President of Strategy & Corporate Development

1981

Sean Christensen

Vice President of Finance and Investor Relations

N/A

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.